Advertisement

Pharmacokinetics of Neostigmine and Pyridostigmine in Man and Its Correlation to Clinical Effects in Myasthenia Gravis

  • S.-A. Eckernas
  • S.-M. Aquilonius
  • P. Hartvig
  • B. Lindstrom
  • P. O. Osterman
  • E. Stalberg
Part of the Advances in Behavioral Biology book series (ABBI, volume 25)

Abstract

Cholinesterase inhibitors, such as neostigmine and pyridostigine, have been in clinical use for more than 40 years as the basic medical treatment in myasthenia gravis. The first investigation of the basic pharmacokinetics was performed by Kornfeld et al. (7) with l4C-labelled pyridostigmine. Later, two different gas chromatographic (GC) procedures for the assay of neostigmine and pyridostigmine were described by Chan et al. (3) and Cohen et al. (6). None of these methods, however, seems to be sufficiently sensitive or selective to permit accurate determination of neostigmine and pyridostigmine in the plasma of myasthenic patients receiving oral treatment.

Keywords

Plasma Concentration Intravenous Administration Cholinesterase Inhibitor Steady State Plasma Concentration Myasthenic Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aquilonius, S.-M., Eckernas, S.-A., Hartvig, P., Lindstrom, B. and Osterman, P.O. (1979): Eur. J. Clin. Pharmacol. 15:367–371.CrossRefGoogle Scholar
  2. 2.
    Aquilonius, S.-M., Eckernas, S.-A., Hartvig, P., Lindstrom, B. and Osterman, P.O. (1980): J. Clin. Pharmacol. 18:425–428.Google Scholar
  3. 3.
    Chan, K., Williams, N.E., Baty, J.D. and Calvey, T.N. (.1976): J. Chromatogr. 120:349–358.CrossRefGoogle Scholar
  4. 4.
    Chan, K. and Calvey, T.N. (1977): Eur. Neurol. 10:69–72.CrossRefGoogle Scholar
  5. 5.
    Chan, K. and Calvey, T.N. (1978): Clin. Pharmaco. Ther. 22: 596–601.Google Scholar
  6. 6.
    Cohan, S.L., Pholmann, L.W., Mikswewski, J. and O’Doherty, D.S. (1976): Neurology 215:536–539.CrossRefGoogle Scholar
  7. 7.
    Cohan, S.L., Dretchen, K.L. and Neal, A. (1977): Neurology 27:299–301.CrossRefGoogle Scholar
  8. 8.
    Kornfeld, P., Samuels, A.J., Wolf, R.L. and Osserman, K.E. (1970): Neurology 20:634–641.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1981

Authors and Affiliations

  • S.-A. Eckernas
    • 1
    • 5
  • S.-M. Aquilonius
    • 1
    • 5
  • P. Hartvig
    • 3
    • 5
  • B. Lindstrom
    • 1
    • 4
    • 5
  • P. O. Osterman
    • 1
    • 5
  • E. Stalberg
    • 2
    • 5
  1. 1.Departments of NeurologyUniversity HospitalUppsalaSweden
  2. 2.Departments of Neurology, NeurophysiologyUniversity HospitalUppsalaSweden
  3. 3.Departments of Neurology, PharmacyUniversity HospitalUppsalaSweden
  4. 4.Department of DrugsNational Board of Health & Welfare25 UppsalaSweden
  5. 5.National Board of Health & Welfare25 UppsalaSweden

Personalised recommendations